Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 159 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Follow-Up Questions
What is the price performance of SMMT stock?
The current price of SMMT is $17.65, it has increased 0.97% in the last trading day.
What are the primary business themes or industries for Summit Therapeutics Inc?
Summit Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Summit Therapeutics Inc market cap?
Summit Therapeutics Inc's current market cap is $13.1B
Is Summit Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 16 analysts have made analyst ratings for Summit Therapeutics Inc, including 4 strong buy, 12 buy, 2 hold, 1 sell, and 4 strong sell
